Clinical Trials Browser

Phase 1/2 × Withdrawn × Anemia, Refractory, with Excess of Blasts × Clear all

NCT06284460 2026-02-13

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Withdrawn

Classical hematologyMyeloid

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders

NCT01163201 2017-12-02

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Phase 1/2 Withdrawn

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Lymphoma, Follicular, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma